Approximately 40–45% of colorectal cancers harbor KRAS mutations (De Roock et al., 2011), and mutation status is predictive of resistance to anti‐EGFR‐based targeted therapy in patients with metastatic colorectal cancer receiving cetuximab or panitumumab (Misale et al., 2014). This evidence concerns the gene KRAS and colorectal cancer.